Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xbiotech Inc
(NQ:
XBIT
)
6.580
+0.460 (+7.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xbiotech Inc
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
June 18, 2024
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
January 04, 2024
From
XBiotech Inc.
Via
GlobeNewswire
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
November 14, 2023
(Phase II Multicenter Study is Proceeding Well with High Anticipation)
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 26, 2023
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
August 30, 2023
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 08, 2023
From
XBiotech Inc.
Via
GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 22, 2023
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 17, 2023
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
October 13, 2022
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France
From
XBiotech Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.